Glembatumumab vedotin is a novel approach in malignancy treatment. This antibody-drug conjugate carefully binds to an protein present on multiple cancer cells, releasing a powerful cytotoxic compound. Early medical https://www.targetmol.com/compound/glembatumumab_vedotin